SGAM
SCMP

Smith Group Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Smith Group Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,680
Closed -$120K – 473
2017
Q4 		$120K Hold
6,680
– – ﹤0.01% 276
2017
Q3 		$79K Sell
6,680
-570
-8% -$6.39K ﹤0.01% 298
2017
Q2 		$76K Sell
7,250
-3,360
-32% -$34.3K ﹤0.01% 301
2017
Q1 		$117K Hold
10,610
– – ﹤0.01% 295
2016
Q4 		$144K Sell
10,610
-340
-3% -$4.74K ﹤0.01% 283
2016
Q3 		$135K Buy
10,950
+220
+2% +$2.59K ﹤0.01% 291
2016
Q2 		$118K Buy
10,730
+4,400
+70% +$49.3K ﹤0.01% 304
2016
Q1 		$69K Buy
6,330
+3,920
+163% +$49.5K ﹤0.01% 292
2015
Q4 		$42K Buy
2,410
+460
+24% +$8.25K ﹤0.01% 347
2015
Q3 		$39K Buy
+1,950
New +$44.7K ﹤0.01% 294
2014
Q3 		– Sell
-2,730
Closed -$19K – 444
2014
Q2 		$19K Hold
2,730
– – ﹤0.01% 308
2014
Q1 		$20K Hold
2,730
– – ﹤0.01% 296
2013
Q4 		$26K Buy
+2,730
New +$19.5K ﹤0.01% 273

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Smith Group Asset Management's SCMP Position: Q1 2018 in Review

Smith Group Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 6,680 shares — an estimated $120K sold.

Smith Group Asset Management first reported a position in SCMP in Q4 2013 and held it in 13 quarters. The position peaked at $144K in Q4 2016. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Smith Group Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Smith Group Asset Management sold 6,680 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $120K.
  • Smith Group Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2013 and held it in 13 quarters.
  • Smith Group Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $144K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Smith Group Asset Management's 13F filing for Q1 2018, filed 8 May 2018.